Net profit of Glenmark Pharmaceuticals reported to Rs 354.21 crore in the quarter ended September 2024 as against net loss of Rs 81.95 crore during the previous quarter ended September 2023. Sales rose 7.59% to Rs 3400.50 crore in the quarter ended September 2024 as against Rs 3160.69 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3400.503160.69 8 OPM %17.7014.63 - PBDT592.85342.53 73 PBT472.57201.07 135 NP354.21-81.95 LP Powered by Capital Market - Live News

Net profit of Glenmark Pharmaceuticals rose 96.81% to Rs 595.06 crore in the quarter ended September 2024 as against Rs 302.35 crore during the previous quarter ended September 2023. Sales rose 19.56% to Rs 2594.89 crore in the quarter ended September 2024 as against Rs 2170.40 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales2594.892170.40 20 OPM %30.0120.43 - PBDT849.91458.89 85 PBT795.06409.04 94 NP595.06302.35 97 Powered by Capital Market - Live News

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live News

Glenmark Pharmaceuticals announced that the United States Food & Drug Administration (USFDA) completed a Good Manufacturing Practice (GMP) inspection at the Company`s formulation manufacturing facility based out of Chhatrapati Sambhaji Nagar (Aurangabad), India. The inspection was conducted from 9 September to 20 September, 2024. The inspection closed with no observationPowered by Capital Market - Live News

Glenmark Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live News